Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

Tiziana Life Sciences (TLSA) announced that Gabriele Cerrone, the Executive Chairman, increased his shareholding by purchasing 60,000 ordinary shares at 55p each, elevating his total stake from 34.208% to 34.238%. This acquisition occurred on October 4, 2021, and is in line with the UK Takeover Code's regulations. Tiziana focuses on innovative therapeutic developments for conditions including oncology and autoimmune diseases, with upcoming Phase 2 studies for Foralumab in Crohn's Disease and multiple sclerosis.

Tiziana Life Sciences plc (NASDAQ: TLSA) announced the court's sanction of its scheme to reorganize into Tiziana Life Sciences Ltd, a Bermuda-incorporated parent company. The scheme, effective on 20 October 2021, includes a two-for-one share consolidation to enhance share value comparability on NASDAQ. Key dates include the last dealings in Old Tiziana shares on 20 October 2021 and trading commencement for New Tiziana shares on 21 October 2021. The company remains focused on developing therapeutics for oncology, inflammation, and infectious diseases.

Tiziana Life Sciences (Nasdaq: TLSA) recently reported that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 100,000 ordinary shares at 52p each. This purchase increased Cerrone's ownership from 34.078% to 34.129%, just above the 1% threshold set by the UK Takeover Code. Tiziana Life Sciences, focused on innovative therapeutics for oncology and inflammatory diseases, is set to initiate Phase 2 studies for its anti-CD3 monoclonal antibody, Foralumab, for treating Crohn's Disease and multiple sclerosis, furthering its pipeline of treatment options.

Tiziana Life Sciences Plc has initiated a strategic restructuring, transitioning to Tiziana Life Sciences Ltd, a Bermuda-based parent company. This move was approved by Scheme Shareholders with 99.11% support at the Court Meeting and a requisite majority at the General Meeting. The Scheme is pending court sanction on October 19, 2021, with an expected effective date of October 21, 2021. The transition will involve the delisting of Old Tiziana shares from the London Stock Exchange and NASDAQ, paving the way for trading of New Tiziana shares.

Tiziana Life Sciences (NASDAQ: TLSA) announced its interim results for the six months ending June 30, 2021, highlighting significant advancements in therapeutic clinical programs. The Phase 1 study of Foralumab demonstrated immunomodulatory effects, while a study in Brazil showed promising outcomes for COVID-19 patients. The company signed an agreement for a Phase 2 study in severe COVID-19 cases and initiated a study for multiple sclerosis. Financially, Tiziana reported a loss of £12.59 million, with R&D expenses increasing to £12.6 million. The firm had cash reserves of £38.6 million at the period's end.

Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) will host a conference call on September 8, 2021, at 4:15 p.m. ET to discuss its exclusive license agreement for evaluating Foralumab, a novel anti-CD3 monoclonal antibody, alongside CAR T candidates for cancer treatment. Interested parties can join via a toll-free line or webcast. A replay will be available until September 22, 2021. Foralumab is recognized for its safety profile in treating autoimmune diseases, making it a significant development in biotechnology.

Tiziana Life Sciences plc (NASDAQ: TLSA) announced the initiation of a strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd in Bermuda as its ultimate parent company. This restructuring, carried out through a scheme of arrangement, aims to enhance the organization’s operational efficiency. Shareholders are invited to virtual meetings on September 27, 2021, to vote on the scheme. Key dates include the effective date for the scheme on October 21, 2021, and the delisting of Old Tiziana Shares and ADSs on the same day.

Precision BioSciences has secured an exclusive license for Tiziana Life Sciences’ anti-CD3 monoclonal antibody, Foralumab, to evaluate its use as a lymphodepletion agent alongside its allogeneic CAR T therapies for cancer treatment. This collaboration aims to enhance the efficacy of CAR T cell therapies by potentially improving their durability and clinical outcomes. Precision will assume development and commercialization duties, while Tiziana will receive upfront and milestone payments along with royalties.

Precision BioSciences (Nasdaq: DTIL) has secured an exclusive license from Tiziana Life Sciences (Nasdaq: TLSA) to utilize foralumab, a human anti-CD3 monoclonal antibody, as a lymphodepletion agent in its allogeneic CAR T therapy development. The collaboration aims to enhance the therapeutic effectiveness of CAR T cells by improving their tolerance and long-term persistence. Precision will oversee the development and commercialization of foralumab, providing Tiziana with upfront, milestone, and royalty payments.